Author:
Wang Jinhai,Lozier Jay,Johnson Gibbes,Kirshner Susan,Verthelyi Daniela,Pariser Anne,Shores Elizabeth,Rosenberg Amy
Publisher
Springer Science and Business Media LLC
Subject
Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology
Reference88 articles.
1. Amalfitano, A. et al. Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 3, 132–138 (2001).
2. Kishnani, P.S. et al. Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68, 99–109 (2007).
3. Goodeve, A. The incidence of inhibitor development according to specific mutations–and treatment? Blood Coagul. Fibrinolysis 14 Suppl 1, S17–S21 (2003).
4. Oldenburg, J. & Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12 Suppl 6, 15–22 (2006).
5. Antonarakis, S.E. et al. Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood 86, 2206–2212 (1995).
Cited by
139 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献